# Novartis Presents Two-Year Ianalumab Results in Sjögren’s Disease

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/54330
Published: 2026-11-11T18:48:45.000Z
Updated: 2026-11-11T18:48:45.000Z
Section: Business

> Results from the NEPTUNUS extension study showed further improvements in disease activity.

Novartis presented long-term results from the NEPTUNUS extension study of ianalumab in Sjögren’s disease. The two-year results showed further improvements in disease activity.